The latest from CDMOs, CMOs, and suppliers featuring Seqens, Alcami, and Asahi Kasei Bioprocess America.  

Chemicals/Chemical API Manufacturing 
* Seqens Names New CEO 
Biologics Manufacturing 
* Asahi Kasei Bioprocess America Names New President 
Formulation Development/Drug Product Manufacturing 
* Alcami Names New Head of Drug Product

---

Chemicals/Chemical API Manufacturing 

Seqens Names New CEO 
Seqens, a CDMO of small-molecule active pharmaceutical ingredients (APIs), intermediates, and specialty ingredients, has announced that Pascal Villemagne, currently CEO of Carbogen Amcis, a CDMO of drug substances and drug products, has been named Chief Executive Officer, effective April 1, 2025. He will succeed Pierre Luzeau, who has served as the CEO of Seqens since 2006 and is joining the Supervisory Board as an Independent Director and Chairman of the Seqens CSR Committee. 

Prior to his tenure at Carbogen, Villemagne held a number of senior commercial and operational leadership positions in the life-sciences sector. His experience encompassed roles as Vice President, Contract Manufacturing, at Farmhispania, a Spanish API contract manufacturing organization, and Sales and Business Development Manager at both Inabata and Cambrex. Earlier in his career, he served as Raw Material Purchasing Manager at Sanofi. 

Source: Seqens 

---

Biologics Manufacturing 

Asahi Kasei Bioprocess America Names New President 
Asahi Kasei Bioprocess America, a subsidiary of Asahi Kasei, has appointed Chris Rombach, current Executive Vice President and Head of Fluid Management, as its President. Rombach joined the company five years ago (2020) and served as a founding member of the Bio-Process Systems Alliance, an industry association focused on facilitating the development and manufacturing of biopharmaceuticals through single-use technologies. 

Source: Asahi Kasei Bioprocess America 

---

Formulation Development/Drug Product Manufacturing 

Alcami Names New Head of Drug Product 
Alcami, a CDMO of drug products and provider of analytical testing services, has announced the appointment of Tori Arens, previously Vice President, General Manager and Site Head for Resilience, as President of Drug Product. 

In this role, Arens will lead the cGMP drug-product manufacturing operations at Alcami. This includes Alcami’s two sterile fill-finish facilities located in Research Triangle Park, North Carolina and Charleston, South Carolina, and oral solid dose drug-product manufacturing, packaging and labeling facilities in Wilmington, North Carolina.

Arens has more than 25 years of experience in the development, technology transfer, manufacture, and supply of drug substances and sterile drug products supporting small molecules, biologics, and gene therapies. She most recently served as Vice President, General Manager and Site Head for Resilience’s facility in Research Triangle Park, North Carolina, for gene-therapy viral vector manufacturing. Her previous responsibilities include Vice President, Drug Product Manufacturing and Supply at Aerie Pharmaceuticals (now Alcon), Director of Parenteral Operations at Biogen, and Senior Director of Parenteral Operations at Eisai. 

Source: Alcami